Read by QxMD icon Read

Current Medical Research and Opinion

David E Trachtenbarg, Carl Asche, Shweta Ramsahai, Joy Duling, Jinma Ren
OBJECTIVE: Multiple surveys show patients want medical privacy, however, there are costs to maintain privacy. There are also risks if information is not shared. A review of previous surveys found most surveys asked questions about patient's privacy concerns and willingness to share their medical information. We found only one study that asked about sharing medical information for better care and no survey that asked patients about the risk, cost or comparison between medical privacy and privacy in other areas...
February 6, 2017: Current Medical Research and Opinion
Alex Z Fu, John J Sheehan
OBJECTIVE: We conducted a retrospective cohort study to investigate the HbA1c change associated with treatment intensification in a real-world population of patients with type 2 diabetes (T2D). METHODS: Using a large U.S. insurance claims database, patients aged ≥18 years with a T2D diagnosis and HbA1c ≥8.0% (64 mmol/mol) after ≥3 months of oral pharmacotherapy with metformin (± other oral antidiabetes agents) were identified (index date). Continuous enrollment was required for ≥12 months before (baseline) and after the index date with no baseline use of injectable antidiabetes drugs...
February 6, 2017: Current Medical Research and Opinion
Fuqiang Yuan, Huijuan Ni, Carl V Asche, Minchul Kim, Saqib Walayat, Jinma Ren
BACKGROUND: The treatment of irritable bowel syndrome (IBS) is a challenge because its cause remains unknown. Previous clinical trials to examine the efficacy of probiotic Bifidobacterium infantis 35624 (B. infantis) in patients with IBS showed inconsistent findings. This study aimed to assess the combined effect of B. infantis on reducing symptom severity of IBS based on the published data. METHODS: A meta-analysis was conducted using fixed-effect models to estimate the combined effect of B...
February 6, 2017: Current Medical Research and Opinion
Krithika Rajagopalan, Sally Wade, Nicole Meyer, Antony Loebel
OBJECTIVE: To compare adherence with lurasidone to other oral atypical antipsychotics among Medicaid and commercially insured patients with schizophrenia. RESEARCH DESIGN AND METHODS: Administrative claims of patients with schizophrenia treated with atypical antipsychotics (lurasidone, aripiprazole, olanzapine, quetiapine, risperidone, or ziprasidone) from October 2010 to September 2011 were identified from MarketScan Commercial and Medicaid Databases, and were classified by the first (index) antipsychotic...
February 6, 2017: Current Medical Research and Opinion
Katerina Papadimitropoulou, Carla Vossen, Andreas Karabis, Christina Donatti, Nicole Kubitz
OBJECTIVE: Major depressive disorder (MDD) affects about 10-15% of the general population in a lifetime. A considerable number of patients fail to achieve full symptom remission despite adequate treatment and are considered treatment resistant (TRD). The current study compared the relative efficacy and tolerability of pharmacological and somatic TRD interventions by means of a Bayesian network meta-analysis. RESEARCH DESIGN AND METHODS: An electronic literature search of MEDLINE, MEDLINE In-Process, EMBASE, PsycInfo, EconLit and Cochrane Library databases for trials published between September 2003 and September 2014 was conducted...
February 6, 2017: Current Medical Research and Opinion
B Tampin, T Bohne, M Callan, M Kvia, A Melsom Myhre, E C Neoh, C Bharat, H Slater
BACKGROUND: The painDETECT questionnaire (PD-Q) has been used widely for the identification of neuropathic pain (NeP); however, the reliability of the English version of the PD-Q has never been investigated. OBJECTIVE: This study aimed to determine the reliability of the PD-Q pre- (T0) and immediately post- (T1) clinical consultation and at one-week follow-up (T2). METHODS: We recruited 157 patients attending a Neurosurgery Spinal Clinic and Pain Management Department...
February 5, 2017: Current Medical Research and Opinion
Clare Saunders, Katie Bayfield, Samantha Irving, Christopher Short, Andrew Bush, Jane C Davies
BACKGROUND: Lung clearance index (LCI) is becoming recognized as an important addition in the monitoring of pediatric cystic fibrosis (CF). The non-invasive technique is easy to perform in all ages, reproducible and increasingly being used in clinical trials. There is interest in utilizing it within the clinic setting but its current use is mostly as a research tool. The procedure is highly dependent on skilled operators and a relaxed testing environment is key to obtaining good quality measurements...
February 2, 2017: Current Medical Research and Opinion
David T Rubin, Snehal Naik, Venkateswarlu Kondragunta, Tharak Rao, Anjali Jain
OBJECTIVE: In 2013 a novel commercial test was launched (Anser ADA test, Prometheus Laboratories Inc.) for the assay of serum adalimumab (ADL) and antibodies-to-adalimumab (ATA). This study aims to understand clinical practice patterns used with ADL in a real-world cross-sectional population. METHODS: Wilcoxon rank sum test, and linear and logistic regression methods were applied in the statistical analysis to test hypotheses. The study design was observational and uncontrolled...
February 1, 2017: Current Medical Research and Opinion
Hsueh-Ju Lu, Peter Mu-Hsin Chang
No abstract text is available yet for this article.
January 31, 2017: Current Medical Research and Opinion
Burak Bilgin, Mehmet A N Sendur, Muhammed Bülent Akıncı, Didem Şener Dede, Bülent Yalçın
BACKGROUND: VEGF, HER2 and EGFR targeted agents are currently used in gastric, esophageal and colorectal cancers. However, treatment outcomes are still poor in most gastrointestinal (GI) cancers. Immune checkpoints are one of the most promising immunotherapy approaches. In this review article, we aim to discuss the efficacy and safety of anti-PD-1/PD-L1 therapies in GI cancers, including gastric, esophageal and colorectal cancer in published or reported recent studies. SCOPE: A literature search was made from PubMed and ASCO Annual Meeting abstracts by using the following search keywords: "nivolumab", "pembrolizumab", "avelumab", "GI cancers" "anti-PD1 therapy" and "anti-PD-L1 therapy"...
January 31, 2017: Current Medical Research and Opinion
Li-Min Sun, Ji-An Liang, Cheng-Li Lin, Ming-Chia Lin, Nai-Jen Chang, Chia-Hung Kao
BACKGROUND: Osteoporosis has been associated with cancer development. We conducted a nationwide population-based cohort study in Taiwan to evaluate this possible association of osteoporosis with subsequent cancer development. METHODS: A total of 35,979 patients diagnosed with osteoporosis between 2000 and 2010 identified from the National Health Insurance Research Database comprised the osteoporosis cohort, and each patient was randomly frequency matched with one individual from the general population (without osteoporosis) based on age, sex, and year of osteoporosis diagnosis to form the non-osteoporosis (control) cohort...
January 31, 2017: Current Medical Research and Opinion
Vibeke Strand, Giampiero Girolomoni, Martin Schiestl, Robert Ernst Mayer, Hilke Friccius-Quecke, Mark McCamish
OBJECTIVE: The aim of this review is to describe the inherent variability that is natural to biologics and, using the proposed etanercept biosimilar (GP2015) as an example, provide details on the 'totality-of-the-evidence' concept, whereby all physicochemical, biologic, preclinical and clinical data for a biosimilar and reference medicine are evaluated in an iterative, stepwise manner and shown to be highly similar. METHODS: This review was carried out by a search of published articles, reviews, abstracts and patents in PubMed/Medline and Google Scholar up to November 2016...
January 30, 2017: Current Medical Research and Opinion
Jodi Strong, Davida Kruger, Lucia Novak
Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Recently approved in the United States and in Europe for use in type 1 and type 2 diabetes, Gla-300 has a more constant and evenly distributed glucose-lowering effect compared with Gla-100, with a duration of action beyond 24 hours and lower within-day and between-day intra-individual variability in blood glucose levels...
January 30, 2017: Current Medical Research and Opinion
Alyssa Goolsby Hunter, Lisa Rosenblatt, Chad Patel, Cori Blauer-Peterson, Beatrice Anduze-Faris
BACKGROUND: In the United States, approximately 3 million people are infected with hepatitis C virus (HCV). Genotypes of HCV variably affect disease progression and treatment response. However, the relationships between HCV genotypes and liver disease progression, healthcare resource utilization, and healthcare costs have not been fully explored. RESEARCH DESIGN AND METHODS: In this retrospective study of patients with chronic hepatitis C (CHC), healthcare claims from a large US health plan were used to collect data on patient demographic and clinical characteristics...
January 27, 2017: Current Medical Research and Opinion
Man Yang, Min He, Miao Zhao, Bing Zou, Jun Liu, Ling-Min Luo, Qiu-Lan Li, Jun-Hui He, Ping-Guang Lei
OBJECTIVE: Proton pump inhibitors (PPIs) are recommended for preventing gastrointestinal lesions induced by non-steroidal anti-inflammatory drugs (NSAIDs). We performed this study: (1) to evaluate the effectiveness and safety of PPIs, (2) to explore the association between effectiveness and potential influential factors, and (3) to investigate the comparative effect of different PPIs. METHODS: MEDLINE, EMBASE, and the Cochrane Library were searched to identify randomized controlled trials comparing different classes of PPIs, or comparing PPIs with placebo, H2 receptor antagonists or misoprostol in NSAIDs users...
January 25, 2017: Current Medical Research and Opinion
Weiqing Wang, Guang Ning, Jianhua Ma, Xiaomin Liu, Shaoxiong Zheng, Fan Wu, Lei Xu, Edward A O'Neill, Kenji P Fujita, Samuel S Engel, Keith D Kaufman, R Ravi Shankar
OBJECTIVE: To evaluate the safety and efficacy of sitagliptin when added to the treatment of patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on acarbose monotherapy. RESEARCH DESIGN AND METHODS: This was a multicenter, randomized, placebo-controlled, double-blind clinical trial. Patients (N = 381) with T2DM and inadequate glycemic control (glycated hemoglobin [HbA1c] ≥ 7.0% and ≤10.0%) on acarbose monotherapy (at least 50 mg three times daily) were randomized in a 1:1 ratio to receive the addition of sitagliptin 100 mg or matching placebo once daily for 24 weeks...
January 25, 2017: Current Medical Research and Opinion
Joseph E Huffstutter, Shelly Kafka, Lawrence H Brent, Marco Matucci-Cerinic, Kezhen L Tang, Marc Chevrier, Trev Sprabery, Raphael J DeHoratius
OBJECTIVE: Evaluate the efficacy and safety of subcutaneous (SC) golimumab + methotrexate (MTX) in patients with active rheumatoid arthritis (RA) despite etanercept + MTX or adalimumab + MTX therapy and evaluate whether intravenous (IV) golimumab could rescue patients who were nonresponders to SC golimumab. METHODS: In this multicenter, assessor-blinded, active-switch study of patients with RA (n = 433) with inadequate response to etanercept or adalimumab + MTX, patients continued MTX and received open-label SC golimumab 50 mg every 4 weeks through week 12...
January 25, 2017: Current Medical Research and Opinion
John Hornberger, Jay Bae, Ian Watson, Joe Johnston, Michael Happich
OBJECTIVE: Amyloid beta (Aβ) positron emission tomography (PET) imaging helps estimate Aβ neuritic plaque density in patients with cognitive impairment who are under evaluation for Alzheimer's disease (AD). This study aims to evaluate the cost-effectiveness of the Aβ-PET scan as an adjunct to standard diagnostic assessment for diagnosis of AD in France, using florbetapir as an example. METHODS: A state-transition probability analysis was developed adopting the French Health Technology Assessment (HTA) perspective per guidance...
January 24, 2017: Current Medical Research and Opinion
Juliana Alvarez Argote, Constantin A Dasanu
BACKGROUND: ASXL1 gene mutations include nonsense, missense, and frameshift mutations. Although their clinical significance is still debated, they may play an important role in the pathogenesis of several hematologic malignancies. METHODS: Herein, we offer a comprehensive review on ASXL1 mutations, and link them with survival and clinical outcomes in patients with various myeloid neoplasms. Most relevant publications were identified through searching the PubMed/Medline database for articles published from inception to February 2016...
January 24, 2017: Current Medical Research and Opinion
William V Tamborlane, Kathryn M Pfeiffer, Meryl Brod, Annie Nikolajsen, Anna Sandberg, Anne L Peters, Michelle Van Name
OBJECTIVE: Despite the increased popularity of newer, fast-acting bolus insulin treatment options that allow for more flexibility in the timing of bolus insulin dosing in recent years, relatively little is known about people with diabetes who administer bolus insulin at differing times in relation to their meals. The purpose of this study was to investigate bolus insulin dose timing in relation to meals among people with type 1 (T1D) and type 2 (T2D) diabetes, as well as to better understand the characteristics and experiences of people who bolus dose at differing times...
January 24, 2017: Current Medical Research and Opinion
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"